Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 10/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23710003 | 1.00 | PDK1 (0.44) | PDK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23698671 | 1.00 | PDK1 (0.44) | PDK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23710002 | 0.86 | TSHR (0.51) | PDK1CHEK1CHEK2ENPP2TSHR | |
| SCHEMBL7371870 | 0.86 | TSHR (0.51) | PDK1CHEK1CHEK2ENPP2TSHR | |
| SCHEMBL22167711 | 0.85 | PDK1 (0.45) | PDK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22167707 | 0.85 | PDK1 (0.45) | PDK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22164071 | 0.85 | PDK1 (0.54) | PDK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23710198 | 0.85 | PDK1 (0.45) | PDK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22164070 | 0.85 | PDK1 (0.54) | PDK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL20797872 | 0.84 | PDK1 (0.48) | PDK1CHEK1CHEK2KDM1AENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| EP-4198034-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198034-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022033567-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | P2RX7, P2RX3, P2RX5 | PDK1 395/4885CHRNB2 4277/4885CHRNA4 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.